Diffuse large B-cell lymphoma trials in Taiwan

In Taiwan 7 Also abroad 346

7 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Kaohsiung City, Tainan, Taipei, Taoyuan City
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Buzi, Changhua, Kaohsiung City, New Taipei City, Niaosong, Taipei, Taoyuan
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 2Taking people
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Where
Kaohsiung City, Tainan, Taipei
Age
65 years to 99 years
People
80 worldwide
Run by
AstraZeneca
See details and how to joinNCT05952024
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Taipei
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
No phaseTaking people
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Where
Kaohsiung, Tainan, Taipei
People
49
Run by
Pell Bio-Med Technology Co., Ltd.
See details and how to joinNCT05377307
Phase 1Taking people
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Where
Taipei
Age
18 years to 70 years
People
18
Run by
GenomeFrontier Therapeutics TW Co., Ltd.
See details and how to joinNCT06703892
No phaseEnrolling by invitation
Long-term Study to Evaluate Safety and Persistence of GF-CART01
Where
Taipei
People
18
Run by
GenomeFrontier Therapeutics TW Co., Ltd.
See details and how to joinNCT06985576